EarningsQ2 2026 Earnings Report
DE:PHE Q2 2026 EPS Results
Actual EPS€0.13
Consensus EPS€0.18
Beat/MissMissed by -€0.05
One Year Ago EPS€0.19
DE:PHE Q2 2026 Revenue Results
Actual Revenue€10.36M
Expected Revenue€11.65M
Beat/MissMissed by -€1.29M
YoY Revenue Growth-9.84%
Earnings Announcement Details
QuarterQ2 2026
Date08/11/2026
TimeAfter Close
Conference CallTuesday, August 11, 2026
DE:PHE Upcoming Earnings
Cipher Pharmaceuticals's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:PHE Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a cautiously positive outlook: while the U.S. business (Natroba) experienced clear top-line pressure—driving a 10% decline in quarter revenue and a 19% decline in Natroba sales versus prior year—the company offset those headwinds with strong margin performance, SG&A reductions, cash generation, year-to-date EBITDA growth (+6% YTD), and concrete commercial and reimbursement progress for Epuris (14% revenue growth, expanded pCPA LOI and 47.1% market share). Management laid out actionable mitigation plans for U.S. channel diversification (DTC, retail, delivery), maintained an opportunistic M&A/in-licensing posture, and preserved liquidity and financing optionality. Overall, positives (sustained high margins, Epuris momentum, cost efficiencies, solid cash and financing capacity) meaningfully outweigh the operational revenue setbacks in the quarter.Company Guidance
Strong Overall Profitability and Margins
Cipher maintained high gross margins (80% in Q2 2026; 81% year-to-date) and strong adjusted EBITDA margins (57% in Q2; 59% year-to-date). The company remains profitable, cash generative, and debt-free.
Year-to-Date Adjusted EBITDA Growth
Adjusted EBITDA for the six months ended June 30, 2026 was $14.6M, up $0.8M or 6% versus the same period in 2025, primarily driven by reductions in SG&A and operational efficiencies.
Epuris: Revenue, Volume and Market Share Gains
Epuris revenue for Q2 2026 was $4.1M, up $0.5M or 14% versus Q2 2025. Sales volumes increased 8% year-over-year in Q2 and market share grew to 47.1% as of June 30, 2026 (a +1.3% change for the first half of 2026), making Epuris the market-leading isotretinoin product in Canada.
Expanded Public Reimbursement Pathway for Epuris
Cipher signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) to pursue public drug plan listings across federal, provincial and territorial plans; final product listing agreements are expected within 30–60 days, which should expand the addressable market and patient access.
Commercial Channel Expansion Initiatives (U.S.)
Management is implementing multiple U.S. growth strategies for Natroba and Spinosad: a first-in-class direct-to-patient platform (telehealth + rapid script routing), direct mail/same-day delivery partnerships, and retail shelf placement (notably a national Walmart program) aimed at diversifying channels beyond Medicaid.
Cost Reductions and SG&A Efficiency
Selling, general & administrative expenses decreased to $3.4M in Q2 2026 from $4.1M in Q2 2025 (a 16% reduction) and to $6.3M year-to-date from $9.0M (a 30% reduction). Reductions were driven by the absence of prior-year non-recurring legal costs and operational efficiencies.
Strong Cash Position and Financing Capacity
Cipher ended the quarter with $9.1M in cash, generated $7.6M of operating cash flow in H1 2026, is debt-free, and has access to up to $90M in potential financing capacity (a $65M revolver plus a $25M accordion).
DE:PHE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed